Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and of Strategic Medicine, Inc, and Strategic Medicine, BV (the Hague, NL) after serving as the Executive Director of the Windber Research Institute from 2003-2007.
He is also an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University. Previously, he was Director, Computational Biology and Biomedical Informatics at the University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics at Rocheharmaceuticals and Director, Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics.
He serves on 14 scientific advisory boards and is on the Board of Directors and chairs the Science Committee of the Nathaniel Adamczyk Foundation for Pediatric ARDS and is an Advisor to the American Heart Association Science and Technology Accelerator. Michael is Chair of the Informatics Program of the PhRMA Foundation and also Chair of its new program in Translational Medicineand Therapeutics and is a member of the PhRMA Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics and the International Park for Translational Biomedicine (Shanghai). He is an Invited Professor at the Shanghai Center for Bioinformatics Technology.
His research focuses on computational models of disease progression stressing risk detection, disease process and pathway modeling and analysis of lifestyle interactions and causal biomarker discovery and focuses on moving bedside problems into the research laboratory to improve patient care and quality of life. Recent activities also include computational approaches to disease modeling, patient and disease stratification, drug safety, reduction of animal testing, the use of genomic data in healthcare, and both qualitative and quantitative risk assessment in health care and the life sciences.